James H Doroshow Selected Research

Poly(ADP-ribose) Polymerase Inhibitors

11/2023	Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.
1/2020	Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas.
2/2017	PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.
1/2016	Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer.
4/2015	Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.
2/2014	Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
1/2013	Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
11/2012	Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
3/2012	A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.
3/2012	Advances in using PARP inhibitors to treat cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James H Doroshow Research Topics

Disease

182	Neoplasms (Cancer) 12/2024 - 05/2002
15	Breast Neoplasms (Breast Cancer) 12/2023 - 05/2002
13	Inflammation (Inflammations) 01/2023 - 06/2004
11	Lymphoma (Lymphomas) 11/2020 - 11/2009
9	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 08/2003
8	Ovarian Neoplasms (Ovarian Cancer) 10/2017 - 10/2004
7	Pancreatic Neoplasms (Pancreatic Cancer) 01/2023 - 04/2011
7	Colonic Neoplasms (Colon Cancer) 11/2021 - 05/2012
7	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 10/2020 - 01/2012
7	Neoplasm Metastasis (Metastasis) 01/2020 - 08/2003
7	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2018 - 01/2004
6	Adenocarcinoma 01/2023 - 11/2006
6	Prostatic Neoplasms (Prostate Cancer) 03/2020 - 02/2004
6	Carcinoma (Carcinomatosis) 01/2020 - 05/2002
6	Hypoxia (Hypoxemia) 12/2017 - 10/2003
5	Sarcoma (Soft Tissue Sarcoma) 09/2023 - 09/2004
5	Carcinogenesis 01/2021 - 04/2013
5	Cardiotoxicity 03/2020 - 09/2004
5	Circulating Neoplastic Cells 01/2020 - 02/2010
4	Alveolar Soft Part Sarcoma 09/2023 - 06/2013
4	Melanoma (Melanoma, Malignant) 01/2023 - 09/2005
4	Hematologic Neoplasms (Hematological Malignancy) 10/2022 - 12/2003
4	Diarrhea 12/2020 - 09/2005
4	Crohn Disease (Crohn's Disease) 12/2019 - 04/2003
4	Genomic Instability 10/2017 - 04/2014
4	Colitis 12/2016 - 04/2003
3	Nausea 12/2020 - 09/2005
3	Vomiting 12/2020 - 10/2003
3	Necrosis 10/2020 - 08/2012
3	Liver Diseases (Liver Disease) 11/2019 - 08/2003
3	Triple Negative Breast Neoplasms 01/2018 - 03/2012
3	Infections 12/2016 - 10/2003

Drug/Important Bio-Agent (IBA)

26	Biomarkers (Surrogate Marker)IBA 04/2024 - 12/2007
23	Proteins (Proteins, Gene)FDA Link 01/2023 - 10/2003
23	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 01/2003
20	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2023 - 06/2004
16	Poly(ADP-ribose) Polymerase InhibitorsIBA 11/2023 - 06/2009
15	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2023 - 06/2009
14	Dual OxidasesIBA 01/2023 - 06/2009
13	Antineoplastic Agents (Antineoplastics)IBA 12/2024 - 01/2003
13	Topotecan (Hycamtin)FDA LinkGeneric 01/2023 - 02/2010
11	CytokinesIBA 01/2023 - 04/2011
11	Messenger RNA (mRNA)IBA 12/2021 - 01/2003
10	EnzymesIBA 11/2023 - 07/2009
10	veliparibIBA 01/2021 - 11/2008
9	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2023 - 10/2003
8	Phosphotransferases (Kinase)IBA 12/2024 - 06/2005
8	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 11/2023 - 11/2008
8	Oxygen (Dioxygen)IBA 11/2021 - 04/2011
8	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2020 - 01/2004
8	Monoclonal AntibodiesIBA 01/2020 - 05/2002
8	Cisplatin (Platino)FDA LinkGeneric 10/2019 - 01/2003
7	Gemcitabine FDA Link 10/2019 - 11/2002
7	PlatinumIBA 01/2018 - 11/2002
7	Type I DNA Topoisomerases (Topoisomerase I)IBA 03/2016 - 07/2009
6	NADPH Oxidase 1IBA 11/2021 - 04/2013
6	Protein Isoforms (Isoforms)IBA 01/2020 - 03/2012
6	Paclitaxel (Taxol)FDA LinkGeneric 01/2020 - 10/2003
6	Docetaxel (Taxotere)FDA Link 07/2006 - 05/2002
5	Temozolomide (Temodar)FDA LinkGeneric 01/2023 - 11/2020
5	Hormones (Hormone)IBA 02/2021 - 05/2002
5	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 10/2003
5	ParaffinIBA 01/2020 - 05/2002
5	Oxidoreductases (Dehydrogenase)IBA 01/2019 - 05/2012
5	Poly Adenosine Diphosphate RiboseIBA 03/2012 - 06/2009
5	Oxaliplatin (Eloxatin)FDA LinkGeneric 11/2009 - 08/2003
4	talazoparibIBA 11/2023 - 02/2014
4	diphenyleneiodoniumIBA 11/2021 - 05/2012
4	PeroxidasesIBA 10/2020 - 06/2004
4	Glutathione (Reduced Glutathione)IBA 10/2020 - 06/2004
4	Oxidants (Oxidizing Agents)IBA 10/2020 - 04/2013
4	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 11/2019 - 10/2016
4	Glutathione PeroxidaseIBA 08/2019 - 04/2003
4	Topoisomerase I InhibitorsIBA 12/2018 - 09/2011
4	AntibodiesIBA 01/2018 - 12/2003
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2016 - 01/2004
3	olaparibIBA 01/2023 - 01/2013
3	cediranib (AZD2171)IBA 01/2023 - 07/2012
3	Drug CombinationsIBA 12/2021 - 08/2011
3	Histones (Histone)IBA 12/2021 - 10/2015
3	pazopanib FDA Link 12/2021 - 07/2012
3	iodonium thiopheneIBA 11/2021 - 05/2012
3	Tamoxifen FDA LinkGeneric 02/2021 - 10/2010
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 06/2015
3	adavosertibIBA 01/2021 - 10/2015
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2020 - 08/2012
3	Formaldehyde (Formol)FDA Link 01/2020 - 03/2018
3	AnthracyclinesIBA 01/2020 - 08/2012
3	Interleukin-4 (Interleukin 4)IBA 11/2019 - 05/2012
3	NSC 724998IBA 12/2018 - 12/2014
3	CamptothecinIBA 12/2018 - 09/2014
3	Small Interfering RNA (siRNA)IBA 12/2017 - 09/2012
3	4,6-dinitro-o-cresol (DNOC)IBA 12/2017 - 05/2012
3	Interleukin-13IBA 06/2017 - 05/2012
3	Bortezomib (Velcade)FDA Link 01/2017 - 02/2006

Therapy/Procedure

57	Therapeutics 04/2024 - 10/2003
22	Drug Therapy (Chemotherapy) 12/2024 - 05/2002
4	Immunotherapy 01/2021 - 01/2016
3	Precision Medicine 06/2023 - 01/2017
3	Aftercare (After-Treatment) 12/2018 - 08/2011